dacarbazine, 4342-03-4

Articles:

PubMed:	Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
PubMed:	Immunotherapy in Melanoma: Recent Advances and Promising New Therapies.
PubMed:	Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.
PubMed:	Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
PubMed:	Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
PubMed:	Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
PubMed:	Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient.
PubMed:	[Vemurafenib (Zelboraf) in the therapy of melanoma].
PubMed:	Lycopene modulates growth and survival associated genes in prostate cancer.
PubMed:	The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
PubMed:	[Antibody therapies for melanoma].
PubMed:	Metastatic melanoma - a review of current and future drugs.
PubMed:	New therapeutical strategies in the treatment of metastatic disease.
PubMed:	Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
PubMed:	Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
PubMed:	Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
PubMed:	Upcoming strategies for the treatment of metastatic melanoma.
PubMed:	Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
PubMed:	Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
PubMed:	Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
PubMed:	New drugs in melanoma: it's a whole new world.
PubMed:	Hematologic adverse events associated with temozolomide.
PubMed:	FDA accelerated approval benefits glioblastoma.
PubMed:	Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
PubMed:	On assessing the presence of evaluation-time bias in progression-free survival in randomized trials.
PubMed:	Malignant melanoma (metastatic).
PubMed:	Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
PubMed:	Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
PubMed:	Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
PubMed:	Neurological adverse effects caused by cytotoxic and targeted therapies.
PubMed:	Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up.
PubMed:	Malignant melanoma (metastatic).
PubMed:	Melanoma: immunotherapeutic approaches.
PubMed:	Genasense: it ain't over till the fat lady sings.
PubMed:	Cutaneous melanoma: available therapy for metastatic disease.
PubMed:	Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
PubMed:	Update on the systemic treatment of malignant melanoma.
PubMed:	Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
PubMed:	Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
PubMed:	A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute.
PubMed:	Intraindividual variations of DNA adduct levels in humans.
PubMed:	Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.